SHANGHAI; BOSTON, Oct 12, 2018 - WuXi AppTec, a leading pharmaceutical and medical device technology platform company, today launched a new DNA-Encoded Library (DEL) Construction & Screening Platform, a cutting-edge technology that expedites the drug discovery process, allowing easy access to more chemical entities in shorter time frames and at lower cost. WuXi’s DEL technology uses unique DNA sequences to tag each chemical entity within a library to enable deconvolution following affinity selection against a target protein. The new platform joins the fleet of existing services provided by WuXi AppTec so that all WuXi partners can access modern, proven, and affordable technologies in drug discovery and development with flexible business terms.
WuXi AppTec started building a strong scientific and technical team led by renowned DEL experts in 2016. The dedicated team consists of interdisciplinary talents in chemistry, biology, bioinformatics and computational chemistry. After two years of preparation, the WuXi DEL platform now features 80 billion unique molecules covering major medicinal-chemically preferred cores, most of which are self-designed and custom-synthesized, making these libraries structurally diverse and chemically exclusive. All the existing libraries are readily screenable and WuXi DEL scientists are continuing to add 10 to 20 billion more compounds to the collection. Through evolutionary screening, the unique drug-like libraries expand the accessible number of drug candidates, leading to better and faster development of new medicines.
Strategically partnering with the genomics experts at WuXi NextCODE, the WuXi DEL team’s unmatched sequencing capacity is supported by world-leading informatics in modeling, mining and interpreting sequencing data. So far, various targets from different classes have been screened and multiple nanomolar hits have been identified. WuXi has proven the readiness of the DEL platform and currently began servicing big pharmaceutical companies, biotech startups and academic clients.
“DEL technology has been well recognized by the pharmaceutical industry in the past decade, and our mission is to empower our clients to expedite their drug discovery projects with this powerful tool,” said Dr. Xuanjia Peng, head of the WuXi DEL team. “Moreover, all the inquiries and orders can be conveniently submitted through our global e-commerce platform, the WuXi LabNetwork. We strive to provide world-class DEL service to all our customers in a simple and client-friendly format. And most importantly we are committed to continuing developing DEL technology to its full potential.”
“WuXi DEL platform is a powerful new capability to enable our customers to explore molecular diversity and generate novel hits for their targets,” said Dr. Steve Yang, Executive Vice President and Chief Business Officer at WuXi. “The new DEL platform will become a key component of our integrated drug discovery technology solution and lower the barrier for innovation.”
About WuXi AppTec
WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and drug R&D and medical device testing, the WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
About WuXi DNA-Encode Library (DEL) Technology Service
WuXi DEL Technology Service provides customers with a cutting-edge hit identification and optimization platform using an affinity-based selection method against DNA-Encoded small molecule libraries. With operations in China, Europe and North America, clients span from small biotechnology companies to big pharmaceutical companies.